Metagenomi Therapeutics, Inc. (NasdaqGS: MGX)
Health Care · Biotechnology · US
$1.22
+0.83% today · -35.3% 1Y
Metagenomi Therapeutics, Inc. (NasdaqGS: MGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $45.71M and employs 113 people.
Over the last twelve months the share price has lost 35.3%, trading between 1.13 and 3.95.
Tweenvest scores Metagenomi Therapeutics, Inc. across four factors: quality 37/100, value 49/100. Its strongest factor is value.
MGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $45.71M
- Revenue (TTM)
- $13.56M
- P/E
- —
- EPS
- -2.49
- Dividend yield
- —
- Beta (5Y)
- 0.67
- 52-week high
- $3.95
- 52-week low
- $1.13
- Avg volume (3M)
- —
- Shares outstanding
- 37.78M
- Employees
- 113
- Next earnings
- —
About Metagenomi Therapeutics, Inc.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
- ISIN
- US59102M1045
- Founded
- 2016
- Listed since
- Feb 9, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.03 | -1.79% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.53 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.67 | -0.07% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.12 | -0.67% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $820.43 | -1.58% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.57 | -7.72% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.